Singapore maintains tariffs on US goods in 2025: report

However, Singapore is vulnerable to a potential 25% US tariff on pharmaceuticals.

Singapore’s tariffs on US goods—and vice versa—will remain unchanged in 2025, according to a report by Natixis CIB. This means Singapore will neither need to lower its tariffs on US goods nor face higher tariffs from the US.

However, Singapore remains among the most vulnerable to a potential 25% US tariff on pharmaceuticals. At the same time, it stands to benefit from the ongoing reshuffling of global supply chains.

According to Natixis CIB, if Trump moves forward with broader tariff measures, the rest of emerging Asia will be negatively impacted, particularly Vietnam, while China could gain a strategic advantage.

Meanwhile, India and Thailand currently have the highest reciprocal tariff differentials with the US.

Currently, only China is subject to Trump-era tariffs, with an additional 20% tariff on top of already high trade and investment barriers. Other Asian countries remain cautious as further trade measures may be introduced in the coming months.

Follow the link for more news on

Chart of the Day

Also Read

OCBC SME Index slips to 49.9 in Q1 after three quarters of growth

RHB maintains 'neutral' rating even as SGX posts strong March

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit